Post-disastrous Valeant investment, soul-searching Ackman reflects on lessons le
One-time Valeant enthusiast and hedge fund manager Bill Ackman has already lamented his huge bet on the now-imploded drugmaker as “one very big mistake.” But now, he’s going a step further, apologizing to investors for that mistake—and reflecting on the lessons he’s learned along the way.
As part of Pershing Square Capital Management’s 2016 annual report, Ackman penned a letter to clients admitting the “huge mistake” that was his Valeant investment and assuming “100% of the responsibility” for the losses they sustained as Valeant’s shares plunged over the last 20 months.
RELATED: Ackman laments his Valeant bet as 'one very big mistake'
“While I and the rest of the Pershing Square team have suffered significant losses from this failed investment as we are collectively the largest investors in the funds, it is much more painful to lose our shareholders’ money, and for this I deeply and profoundly apologize,” he wrote of the 19.2% hit Pershing’s Valeant stake took for the year.
But the episode was not without its learning opportunities, he stressed. Some of Pershing’s key takeaways from the experience: You can’t assign material value to a management team’s dealmaking history; regulations, politics, and other uncontrollable factors can take a pretty big bite out of a company’s intrinsic value; and even a management team with a strong track record can slip up—big time—every once in a while.
RELATED: Billions in the hole, battered hedge funder Ackman finally ditches his long, painful Valeant investment
Ackman’s look back comes just a couple of weeks after Pershing Square’s decision to bail on its longtime investment in the embattled Canadian drugmaker. Over the course of his Valeant involvement, as things went from good to bad to worse, he served as the company’s hostile M&A pursuit partner, cheerleader, activist investor and, eventually, board member.
And while he applauded the new management team’s recent efforts to get back on track, he also defended his decision to finally part ways with the foundering company. “While Valeant has made significant progress and we expect management to continue to do so, there is still a lot of work to be done,” he noted.
Meanwhile, Valeant—under multiple investigations and facing debt-default worries, poor product sales and federal charges against a former employee, to name a few of its hurdles—hasn’t been able to right the ship since new skipper Joseph Papa took over last spring. That didn’t stop the company from awarding him a $62.7 million pay package, though, missed financial targets aside.
Looking for chemical products? Let suppliers reach out to you!
2026-07-10
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
The project of fine chemicals with 4000 t/a Tebuconazole and Diflufenican is to be built
-
Pharmaconex 2022
-
CPHI Korea 2022
-
Shandong Pharmaceutical Companies Grab Over $1 Billion of Antithrombotic Drugs for The First Imitation, Original Research Drugs Soared 5527%
-
ECHEMI International Trade Business School Bangladesh Pharmaceutical Summary
-
Industrialization Progress of genetically modified pharmaceutical products
-
2022 Top 50 Global Pharmaceutical Companies Released! Pfizer Returns to NO.1, Kexing Counterattack First on the List
-
Pharmaceutical and Health Industry Special Study - The Arrival of New Opportunities
-
Accelerate Technological Breakthroughs in Product Innovation and Promote the Industrialization and Application of Innovative Drugs
-
The Rare Disease Market Continues to Heat Up. How Will The Global Top 10 Pharmaceutical Companies by Revenue in 2021 be Deployed?
Recommend Reading
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
NHU and Sinopec Advance Liquid Methionine Project
-
J&J VAT Dispute Threatens Free Medicine Access in Britain
-
Pfizer Warns Germany: Drug Pricing Could Put Investment at Risk
-
Vertex Buys Crinetics for $10 Billion: Rare Disease M&A Is Back
-
In 2025, China's hydrofluoric acid prices fluctuated upward; in 2026, the price level may continue to rise
-
Mitsubishi Chemical Announces Expansion of Advanced Carbon Fiber Production Capacity in Japan and the United States
-
2025 Toluene Market Fluctuates Downward, 2026 Supply and Demand Competition Outlook
-
Uses of Sodium Acetate Trihydrate
-
“An €8 Billion Loss, Yet a 25% Price Hike”: Wacker Chemie’s Contradictory Crisis—Survival Move or Desperate Gamble?